Enanta Pharma (ENTA) Misses Q2 EPS by 14c

Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($1.53), $0.14 worse than the analyst estimate of ($1.39). Revenue for the quarter came in at $19.5 million versus the consensus estimate of $20.65 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Oceanfirst Financial (OCFC) Tops Q1 EPS by 3c
• Infosys Limited (INFY) Tops Q4 EPS by 5c; offers FY25 guidance
• Metropolitan Bank Holding Corp (MCB) Tops Q1 EPS by 12c